News Regeneron is off to CHAPLE as FDA starts pozelimab review The C5 inhibitor is vying to become the first approved drug for the ultra-rare immune disorder.
Events Partner Content Welcome to the 6th Complement-based Drug Development Summit ... Decipher Complement Pathway Intricacies, Validate Pathway Activation Assays & Discover Next-Generation Complement-Targeted Approaches that are